Leadman(SZ:300289)2026-01-29 09:04Financial Performance - The company expects a net loss of between RMB 15 million and RMB 28 million for the fiscal year 2025, compared to a net loss of RMB 75.1 million in the same period last year [3]. - The net profit after deducting non-recurring gains and losses is projected to be a loss between RMB 24 million and RMB 37 million, compared to a loss of RMB 97.5 million in the previous year [3]. - The estimated impact of non-recurring gains and losses on net profit for the current period is approximately RMB 9 million, primarily from government subsidies and fair value changes, compared to RMB 22.37 million in the same period last year [5]. Business Challenges - The decline in main business revenue and gross margin of diagnostic reagent products is attributed to the expansion of domestic diagnostic reagent centralized procurement, further implementation of DRG/DIP policies, and intensified industry competition [5].